Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Comment by TheTerminator1on Jun 30, 2021 12:41pm
100 Views
Post# 33473635

RE:RE:RE:RE:RE:RE:RE:Merck knows the importance of RVV's Bucillamine

RE:RE:RE:RE:RE:RE:RE:Merck knows the importance of RVV's BucillamineStop with BS Ott >>> 

Click on Link >>>Revive Therapeutics Approved to Trade on the OTCQB Market


Excerpt form the last PR >>>

Michael Frank, CEO of the Company commented, "We are focused on completing our Phase 3 study in COVID-19 with the aim to seek EUA approval from the FDA for Bucillamine in the treatment of mild to moderate COVID-19 patients, and advancing our proprietary psychedelics program in developing novel uses and delivery forms of psilocybin to treat mental health and substance abuse disorders. With our common shares listed on the OTCQB it will help us to broaden our awareness and shareholder base with institutional and retail investors in the U.S.”


TheTerminator1 wrote: Is that right....Your behind on your DD or playing the stupid game

1ottrunner wrote: Institutional buyers will have ZERO to do with a penny stock.

You do know this, right?

I'm not telling you something you don't know, correct?  


TheTerminator1 wrote: I will let US Institutional Buyers do all the talking if you are smart enough to know what i mean!!!

1ottrunner wrote:

You made the statement.  You have to prove it.  You can't ask me to prove your BS wrong.

Do you think posting idiotic BS here helps the SP?  Are you dumb enough to believe that you have some control over the market from Stockhouse?

 

 

TheTerminator1 wrote: Prove me wrong
 

 

1ottrunner wrote:

Merck does?  BS!  Offer some realiable DD on this.

Why post rediculous garbage?

 

TheTerminator1 wrote: Lots of good new news to come for RVV shareholders

Stay connected

 

 


 

 

 

 




<< Previous
Bullboard Posts
Next >>